Aquatic Capital Management LLC Increases Holdings in Insmed Incorporated (NASDAQ:INSM)

Aquatic Capital Management LLC raised its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 296.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,268 shares of the biopharmaceutical company's stock after purchasing an additional 68,268 shares during the period. Aquatic Capital Management LLC owned approximately 0.05% of Insmed worth $6,301,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in Insmed in the 4th quarter valued at approximately $126,606,000. Vanguard Group Inc. grew its stake in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Insmed by 59.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock worth $113,748,000 after buying an additional 615,000 shares during the period. Capital International Investors grew its position in Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after acquiring an additional 593,206 shares during the period. Finally, B Group Inc. acquired a new position in Insmed during the fourth quarter worth $24,164,000.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 33,055 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the completion of the transaction, the insider now owns 138,053 shares of the company's stock, valued at approximately $11,168,487.70. This trade represents a 19.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 380,657 shares of company stock worth $30,330,039 over the last three months. 3.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on INSM shares. UBS Group raised their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Stifel Nicolaus reduced their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Bank of America raised their price target on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research note on Thursday, March 20th. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Trading Up 0.6 %

NASDAQ INSM traded up $0.41 during mid-day trading on Friday, reaching $73.05. 699,938 shares of the stock were exchanged, compared to its average volume of 2,303,218. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market cap of $13.28 billion, a P/E ratio of -13.07 and a beta of 1.07. The stock has a 50 day simple moving average of $73.53 and a 200-day simple moving average of $73.50. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. On average, analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.